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Abstract 
Ischemic heart disease is the leading cause of death, and reperfusion which can restore blood 
flow is the primary therapy. However, reperfusion can induce further damage to 
cardiomyocytes, a condition described as ischemia-reperfusion (I/R) injury. I/R is now 
recognized as a combination determining the final myocardial infarction size. Although 
the mechanisms underlying I/R-induced cardiac injury remain incompletely understood, 
emerging evidence suggests that intracellular Ca2+ mishandling during I/R plays a key role in 
cell death. Junctophilin-2 (JPH2) is a junctional membrane-binding structural protein. It 
mechanically maintains the fixed distance between the T-tubule and the sarcoplasmic 
reticulum (SR), thus allowing the proper Ca2+ -induced Ca2+ release for stable excitation-
contraction coupling. Down-regulation of JPH2 has been observed in diseased hearts and is 
related to cardiac dysfunction and T-tubule remodeling. In this study, we show that the 
protein levels of JPH2 are down-regulated in cardiomyocytes following 
hypoxia/reoxygenation (H/R), a condition simulating I/R. Up-regulation of JPH2 protects 
cardiomyocytes against H/R-induced apoptotic cell death. Furthermore, we reveal that up-
regulation of JPH2 reduces ryanodine receptor-2 (RyR2)-mediated SR Ca2+ leak and inhibits 
calcium-dependent calpain activation in H/R-stimulated cardiomyocytes. Lastly, up-
regulation of JPH2 prevents endoplasmic reticulum stress in response to H/R. In summary, 
we demonstrate for the first time that JPH2 prevents H/R-induced apoptosis by blocking Ca2+ 
leakage via RyR2 in cardiomyocytes. Thus, up-regulating JPH2 may represent a new 
therapeutic strategy to treat ischemic heart disease. 
Keywords 
Cardiomyocytes; Junctophilin-2; RyR2; Calcium; Calpain; ER stress; JNK1/2; Apoptosis; 
hypoxia/reoxygenation 
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Chapter 1  
1 Introduction 
1.1 Myocardial ischemia/reperfusion injury 
Cardiovascular disease (CVD) is the leading cause of death globally. It kills more than 
17.3 million people per year, and the number is predicted to climb to 23.6 million by 
2030 [1]. In Canada, 1.6 million people are suffering from CVD, and more than 66,000 
Canadians die from it each year, nearly one death every seven minutes [2]. Ischemic heart 
disease (IHD), also known as coronary artery disease (CAD), is the most common and 
deadly type of CVD, accounting for 46% of cardiovascular deaths in men and 38% in 
women [3]. 
Most IHDs are related to coronary atherosclerosis, a formation of plaque involving 
intense inflammatory and immunological developments on the artery wall [4]. A 
narrowed coronary artery cuts down the blood flow to supply myocardial oxygen and 
nutrients, which decreases ATP generation and causes myocardial injury [5]. The most 
severe manifestation is when the atherosclerotic plaque ruptures and completely occludes 
the coronary artery, a condition called myocardial infarction [6]. A short period after 
oxygen deprivation (ischemia), anaerobic glycolysis engages and substitutes oxidative 
phosphorylation as the significant source of ATP production to maintain the basic energy 
demand in the myocardium [7]. Cardiac contraction is abated to reduce energy demand in 
the same way as the ATP-consuming biosynthetic processes including gluconeogenesis 
and lipid and protein synthesis. However, if the ischemic event continues, the glycolytic 
pathway is unable to remedy ATP depletion and insufficient to maintain the minimal 
cellular metabolism [8]. The entire cardiomyocyte becomes swollen due to the influx of 
sodium and water caused by the failure of the ATP sodium pump, leading to cytoskeleton 
dispersion, a dilated endoplasmic reticulum, and the formation of "blebs" at the cell 
surface [9]. Even at this point, the cellular derangement is still repairable if the hypoxia 
can be reversed. If ischemia duration further extends, intensely disturbed intracellular 
ions, especially impairment of Ca2+ homeostasis, activates membrane-bond endogenous 
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phospholipase and consequently accelerates the degradation of membrane phospholipids 
[10]. As a result, plasma and organelle membranes are dysfunctional. Once the cells lose 
the permeability barrier, the cellular damage becomes irreversible, and necrosis ensues 
[11]. Accordingly, the crucial step to rescue the myocardium from lethal cell injury is to 
remove the ischemic condition when the damage remains reversible. Studies of 
reperfusion were initiated 40 years ago by Marko et al. [12] and Ginks et al. [13], and it 
has been proven that therapies to restore blood flow in ischemic myocardium salvage 
reversibly injured cardiomyocytes from necrosis. Since then, reperfusion strategies like 
thrombolysis, intervention, and bypass surgery have been widely incorporated into 
clinical practice during the last three decades [14]. This therapy limits the extent of 
infarct size, preserves the cardiac contraction function, and prevents the onset of heart 
failure, which all ultimately lead to a significant reduction in the acute mortality after 
myocardial infarction [15]. However, as a result of a decrease in mortality rate for acute 
myocardial infarction due to improved reperfusion therapies, there is an increase in the 
incidence of heart failure after myocardial infarction [16]. Post-myocardial infarction 
heart failure is now the most rapidly rising cardiovascular condition to affect the lives of 
Canadians. Over 500,000 Canadians are afflicted with heart failure, and up to 50% of 
them die within five years of diagnosis [17]. Thus, myocardial infarction and subsequent 
heart failure is a tremendous personal struggle for Canadians and a significant financial 
burden for our health care system [18]. 
In fact, studies have shown that reperfusion itself induces further disruptions and 
additional injuries secondary to the ischemic damage, a condition described as 
“ischemia/reperfusion (I/R) injury” [19]. I/R injury not only reduces the benefits of blood 
flow restoration but also converts a population of cardiomyocytes from reversible to 
irreversible injury [4, 5]. The four most recognized forms of I/R injury include 
arrhythmia, myocardial stunning, microvascular obstruction, and lethal myocardial injury 
[20]. Paradoxically, although reperfusion could damage the myocardium, which may 
cause heart failure later, until now, there has been no better solution than this strategy to 
rescue the severe acute ischemic heart from a total dysfunction. Therefore, the clinical 
research has shifted from solely ischemic damage to I/R injury together as the important 
combination contributing to the final myocardial infarct size [21]. 
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For many years, necrosis was the predominant form of I/R-induced cell death [22]. This 
random, uncontrolled sudden cell death happens to those already-damaged ischemic cells 
in the initial minutes after reperfusion in response to the overwhelming stress [23]. 
Recent studies have revealed that apoptosis is not only involved in the I/R injury but also 
has a significant contribution to the IR injury [24]. Unlike necrosis, this programmed, 
energy-consuming form of cell death happens to those peripheral ischemic cells that 
suffer lower damage comparing to the central ischemic cells and survive the initial 
minutes of reperfusion [25]. These cells can be rescued since apoptotic progression 
requires time and can be regulated. Therefore, prevention of late apoptosis in prolonged 
reperfusion has attracted more attention as a therapeutic strategy to reduce IR injury after 
myocardial infarction [8, 25, 26]. Although the mechanisms of I/R-induced cell death 
(necrosis and apoptosis) have not been completely understood, ample evidence suggests 
that calcium overload and altered calcium handling is one of the major mediators 
initiating disruption and lethal cell injury.  
1.2 Ca2+ mediated cell death in ischemia-reperfusion 
1.2.1 Ca2+: a universal second messenger 
In the long-time river of evolution, the selection of Ca2+ as the universal carrier of signals 
had been the hallmark of the transition from the unicellular to the multicellular life form 
[27, 28]. The exchange of intercellular signals allows a higher level of functional 
interplay and coordination among the cells of the organisms other than just the 
competition of nutrients [27]. However, extracellular-secreted signal molecules are 
complex and mostly act as a first messenger that binds to the receptors on the target cell 
membrane and may not cross it. Thus, it requires the second messenger to interact and 
transmit the signals within the cell [29]. The Ca2+, given its chemical properties, is one of 
the perfect molecules to accommodate the binding signals. Unlike other active-site metals 
that directly participate in the enzyme catalysis, Ca2+ is an allosteric metal and binds to 
the sites that are different from the active site [30]. This character makes Ca2+ a better 
modulator to enzyme proteins since it has the capacity not only to activate but also to 
inhibit them [31]. Moreover, Ca2+ can also be controlled tightly, based on its 
characteristics: binding it reversibly, with particular concentration and appropriate 
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affinity to cellular proteins [32]. For these reasons, Ca2+ has been selected as a universal 
intracellular messenger that regulates numerous general biological processes to all cells, 
such as gene transcription, metabolic pathways, differentiation, and cell growth or death. 
It also regulates other cell-specific processes like neural regulation and muscle 
contraction [33]. 
1.2.2 Ca2+ signaling in cardiomyocytes 
Normal cardiac function and myofilament contraction rely on Ca2+ signaling which 
transfers the depolarizing current to the contractile force of each sarcomere [34]. In every 
cardiac cycle, a depolarizing action potential is derived from the sinoatrial (SA) node. 
This current spreads through the right to the left atrium and pauses for a 0.1-s period (in 
humans) when arriving the atrioventricular (AV) node, to complete the atrial systole. 
After the short stop, the depolarization spreads through the Purkinje fibers to the left right 
ventricular separately to finish the whole cardiac contraction cycle [35]. When 
depolarizing action current reaches the T-tubules, it triggers the L-type Ca2+ channels 
(LTCCs) to release small flows of Ca2+ (Con < 10 μM, or “sparklet”) into the gap called 
dyad cleft between the cell membrane and the sarcoplasmic reticulum(SR)/endoplasmic 
reticulum(ER) [36]. The "sparklet Ca2+" induces the opening of ryanodine receptors 
2(RyR2) which is plasmalemma-situated on the SR. It consequently mobilizes a large 
Ca2+ flow (Con >100 μM) releasing into the dyad cleft as known as "Ca2+ spark", a 
phenomena described as “Ca2+-induced Ca2+ release (CICR) or Ca2+ coupling” [37].  
During a single action potential, thousands of RyR2 sites are simultaneously activated by 
their corresponding L-type VOCCs provided "Ca2+sparklet" in dyad cleft. This process 
produces an average global Ca2+ increase of 500 nM to ~1 μM [38]. This amount of Ca2+ 
subsequently engages the Ca2+-binding component, troponin (TnC), which is sensitive 
over that range. It triggers the filaments shorting to provide the contractile force for 
pumping blood [39]. In the end, these unique junctional membrane complexes (JMCs) 
successfully transport an action current to create a synchronic sarcomere contraction of 
each article and ventricle. After triggering the contractile units, Ca2+ dissociates from the 
TnC and rapidly removes from the cytosol to prepare for the next round of CICR [40]. 
The efflux of dissociated Ca2+ is mainly taken back to the SR by sarco/endoplasmic 
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reticulum Ca2+ ATPase (SERCA2a) pump [41] and goes through extrusion by the cell 
membrane Na+/Ca2+ exchanger (NCX) [42]. 
 
Figure 1: Ca2+ cycling in cardiomyocyte, cited from[43] 
1.2.3 Ca2+ homeostasis in cardiomyocytes 
Considering Ca2+ is imperative in the excitation-contraction (EC) coupling of each 
cardiomyocyte, it is of utmost importance to maintain a low intracellular diastole Ca2+ 
concentration, which guarantees a simultaneous sarcomere contraction in the next cardiac 
beating cycle [27]. Besides, the Ca2+ carrying signals modulate the enzyme process and 
other essential biochemical activities through its precisely controlled elevation in the 
cytosol and subcellular compartments [30]. So, after the transit elevation demanded by 
the contraction, Ca2+ concentration should return to the low/intermediate nM range. A 
protracted Ca2+ increase can trigger abnormal activities that the cells cannot tolerate [44]. 
In cytosol, the concentration of free Ca2+ is normally maintained to be as low as at 100 to 
200 nM. SR luminal Ca2+ is one of the main sources, and it can raise the cytosol Ca2+ 
concentration to over 100 μM during the CICR, as mentioned above [37]. Extracellular 
Ca2+ is another important source, in which the Ca2+ concentration fixed at 3mM, with 
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approximately half being ionized [45]. The luminal SR deposit ensured the fast reaction 
of mobilizable Ca2+, which contributes to the sarcomere contraction, along with the high-
concentration extracellular pool that creates a large gradient and electrochemical force on 
Ca2+ to entering the cell conveniently as a second messenger and modulator [39]. The 
transport of Ca2+ across membranes is precisely controlled by a set of different 
components in cardiomyocytes, including channels (L-type Ca2+ channels and RyR2 
receptors), ATPases (sarco/endoplasmic reticulum Ca2+ ATPase), and exchangers 
(Na+/Ca2+ exchanger), all of which are directly engaged in the process of CICR [34]. 
Other components, such as store-operated Ca2+ entry channels (SOCEs), inositol-(1,4,5)-
trisphosphate receptors (InsP3R), and plasma membrane Ca2+ ATPase (PMCA) also 
participate in cytosol Ca2+ regulation and stabilization [46]. Furthermore, Ca2+ -binding 
proteins are another crucial system maintaining intracellular Ca2+ homeostasis. Some of 
them are pure buffering proteins, like calsequestrin, which are contained in SR and 
determine the calcium storage [47]. Calsequestrin also coordinates with RyR2 for 
regulating Ca2+ release during the process of EC coupling [48]. Others named Ca2+ 
sensors, like calmodulin (CaM), not only regulate the Ca2+ concentration but also process 
and decode the Ca2+ signal. CaM mediates the action of cyclic ADP-ribose (cADPR), 
which acts as an endogenous regulator of CICR in cardiomyocytes [49]. Using 
immunoblot assays, Lee, Aarhus, and Graeff (1995) found that CaM was responsible for 
conferring the sea urchins eggs an increased sensitivity to cADPR, thus playing a critical 
role in calcium homeostasis [50]. 
Thanks to this strong adjusting and buffering system, Ca2+ is tightly regulated in 
cardiomyocytes. However, under some conditions of overwhelming stress and 
pathogenesis, Ca2+ could lose its homeostasis, and the most common situation is the 
cytosol could not maintain the low basal concentration [51]. The first impact of the Ca2+ 
dysregulation would be the contraction process. Termination of CICR is largely 
dependent on the depletion of calcium. Thus, if Ca2+ is not removed, CICR will remain at 
peak levels, and cardiac relaxation will not be achieved [52]. Apart from being a cellular 
powerhouse, mitochondrial ability to handle elevated cytosolic Ca2+ is critical to cellular 
processes and survival [53]. However, the excessive influx of Ca2+ could impair the ATP 
synthesis and production [54]. Endoplasmic reticulum (ER) is the major Ca2+ storage and 
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is sensitive to the Ca2+ environment changes [55]. An altered Ca2+ level would render the 
ER incapable of supporting cellular functions, such as assembly and folding proteins 
[56]. The impairment of calcium regulation would also induce over-activation of some 
enzymes or proteases, such as calpain, which causes further disruption and damage to the 
cells [57]. A disturbance in calcium homeostasis is, therefore, important in pathological 
development. 
1.2.4 Ca2+ overload after ischemia/reperfusion 
When ischemia occurs, intracellular PH declines progressively due to increased H+ that is 
released by anaerobic glycolysis. The increased H+ activates the primary extrusion 
mechanisms of the Na+/H+-exchanger (NHE) and the Na+-HCO3 cotransporters [58]. The 
fast Na+ influx and the inhibited Na+/K+-ATPase, because of the insufficient ATP 
production, both contribute to the cytosolic Na+ overload [59]. After the rise of Na+, the 
Na+/Ca2+ exchanger (NCX) is converted into its reverse mode, which extrudes the Na+ 
but brings in the Ca2+ [60]. The low ATP concentration also impaired the sarcoplasmic 
reticulum Ca2+-ATPase (SERCA), which further develops the intracellular Ca2+ 
substantial accumulation and overload [61] [Figure 2]. At the onset of reperfusion, 
extracellular H+ is quickly removed by the restored blood flow [62]. The accelerated H+ 
efflux, through the reactivated NHE and Na+-HCO3 cotransporters, corrects the 
intracellular pH but also aggregates Na+ overload and the consequent Ca2+ overload [59]. 
The exacerbated Ca2+ overload causes lethal cell injury, mainly through hypercontraction, 
calpain-mediated proteolysis, and mitochondrial permeability transition [63]. These 
injuries have been demonstrated to cause necrotic cell death shortly after the reperfusion 
in cardiomyocytes close to the ischemic artery. However, the mechanism of late apoptotic 
cell death in surviving cardiomyocytes remains incompletely understood. These 
cardiomyocytes stay farther from the ischemic artery and suffer minor Ca2+ dysregulation 
[59, 62, 64]. The reason why they still undergo apoptosis later after I/R requires further 
investigation.  
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Figure 2: Ca2+ overload after ischemia, cited from [65] 
 
1.3 Junctophilin-2 
1.3.1 The biophysiology of JPH2  
In the year 2000, junctophilin (JPH) was first discovered in rabbit skeletal muscle and 
defined as a crucial member of junctional membrane complexes (JMCs) [66]. Four 
different isoforms are found in the JPH family (JPH 1-4), in which JPH1 is mainly 
expressed in skeletal muscle, and JPH3 and JPH4 are widely expressed in the neurons 
and brain [67, 68]. Junctophilin-2 (JPH2) is the predominant cardiac isoforms. It is 
encoded by the JPH2 gene, which incorporates five coding exons at 20q13.12 [69]. The 
GO annotations associated with the JPH2 gene consist of phosphatidylinositol-4 and 
phosphatidylinositol-3-phosphate binding, as well as 5-bisphosphate binding [70]. 
Substitute splicing has been experienced at this locus and two variations coding different 
isoforms are defined [71]. In human cardiomyocytes, the JPH2 gene encodes a 74kDa 
protein JPH2 with 696 amino acids [72]. It has eight times repeated MORN motifs (14 
amino acid residues) in the N-terminal domain, which binds to the plasma membrane or 
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sarcolemma (T-tubules). At the opposite side, its C-terminal transmembrane segment 
spans the SR/ER membrane. In a putative α-helical region (∼100 amino acids residues) 
forms the structural body basis for this bridging protein [66, 68, 70]. 
1.3.1.1 Role of JPH2 in JMCs construction  
Junctional membrane complexes (JMCs), as mentioned above, were first observed in the 
mid-'50s by Porter and Palade [73]. They are found in all kinds of excitable cells [74, 75]. 
This unique channel's cross-talk structure is necessary for E-C coupling [52, 76]. It has 
been demonstrated that JPH2 is the key anchoring molecule, which mechanically 
maintains the fixed distance between the T-tubule and sarcoplasmic reticulum (SR) [43, 
77]. The importance of JPH2 for JMCs in hearts was first discovered by Takeshima et al. 
in JPH2 knockout mice, which exhibited a defective coupling area with randomly 
irregular Ca2+ transients. Due to the contractile disability, these mice were embryonically 
lethal at E10.5 [66]. Wehrens's group, using inducible cardiac-specific JPH2 knockdown 
mice, confirmed the reduction of JMCs and further demonstrated a causal link between 
loss of JPH2 and defective CICR within JMCs. They crossed shJPH2 mice with α-
myosin heavy chain (αMHC)-MerCreMer (MCM) mice to ensure cardiac-specific 
shRNA expression. MCM-shJPH2 mice with impaired EC coupling also developed acute 
contractile and heart failure [78]. Together, these studies show that JPH2 is an essential 
component that reinforces the structural stability of the JMCs formation, ensuring the 
CICR for stable EC coupling. 
1.3.1.2 Role of JPH2 in T-tubule development  
Transverse tubules (T-tubules) are physical extensions of the surface sarcolemma, which 
invaginate deep into the interior ventricular myocytes and along with the Z-line [79]. It 
transports the depolarizing current to Ca2+ signals via L-type Ca2+ channels (LTCCs), 
which initiate the process of CICR and excite the cardiomyocytes for contraction [80]. In 
neonatal mammalian cardiomyocytes, T-tubules are absent, and the EC coupling was 
conducted by direct Ca2+ influx through promoted sodium-calcium exchanger (NCX) at 
the periphery of the cell [81]. During the early postnatal stage, the development of the T-
tubule network is one of the hallmarks of myocytes maturation, and JPH2 plays a critical 
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role in this process [82]. Studies from Chen et al. [83] and Reynolds et al. [84] both 
demonstrated that cardiac-specific silencing of JPH2 significantly reduced T-tubule 
organization in the heart during the postnatal stage. In contrast, overexpression of JPH2 
accelerated T-tubule maturation by postnatal day 8 [84]. It is highly likely that JPH2 can 
anchor the invaginating sarcolemma to the SR, thereby triggering the development of 
mature T-tubules, which allows full EC-coupling for maximized contraction capacity. 
1.3.1.3 Role of JPH2 in RyR2 stabilization  
Ryanodine receptor 2 (RyR2) is a crucial component of JMCs in cardiomyocytes. It acts 
as the major SR/ER-stored calcium release channel, which directly participates in CICR, 
in charge of SR Ca2+ mobilization for myofilament contraction [76]. Emerging evidence 
suggests that JPH2 has a functional regulatory role in RyR2 stability in addition to the 
JMC structural integrity. Immunoprecipitation targeting RyR2 from mouse heart tissues 
"pulled down" JPH2, suggesting a potential direct interaction between RyR2 and JPH2 
[85]. Recent super-resolution imaging studies of immunofluorescence staining on rat 
ventricle tissues confirmed a strong molecular-scale co-localization between JPH2 and 
RyR2, indicating a direct interaction between them [86, 87]. Studies on adult-onset JPH2 
knockdown mice showed abnormal Ca2+ release through RyR2 and decreased EC-
coupling gain, supporting a regulatory role of JPH2 in RyR2 [88]. Furthermore, Calcium 
imaging and single channel RyR2 recording studies in ventricular-isolated 
cardiomyocytes from JPH2 knockdown mice indicated that JPH2 was a negative 
regulator of RyR2-gating. The loss of JPH2 resulted in aberrant Ca2+ leakage from 
SR/ER through RyR2 [89] [Figure 3]. These data strongly support a new role of JPH2 in 
regulating RyR2 function in cardiomyocytes. However, its pathophysiological 
significance remains to be determined in the heart.  
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Figure 3: Ca2+ leakage through RyR2, cited from [77] 
 
1.3.2 JPH2 and heart diseases 
1.3.2.1 Mutations of JPH2 associated with hypertrophic 
cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a cross-age genetic disorder which enlarges a 
portion of myocardium without external stimulations [90]. It is the leading cause of 
sudden cardiac death of young athlete and mostly asymptomatic beforehand [91, 92]. The 
study from Matsuoka's group on murine genetic models first implicated JPH2 
dysregulation to HCM and dilated cardiomyopathy [93]. This finding was supported by a 
clinical study where down-regulated JPH2 was observed in surgically resected 
myocardium from human HCM patients [94]. This study also looked into whether loss of 
JPH2 was sufficient to initiate the myocardial hypertrophy. JPH2 acute suppression in 
HL-1 cells increased the cellular size and induced hypertrophic process with up-
expression of several transcriptional markers such as atrial natriuretic factor, brain 
natriuretic factor, myosin heavy chain, and skeletal actin. The JPH2 expression silencing 
also reduced the transient amplitude and altered Ca2+ homeostasis [94]. Based on these 
findings, several studies have been conducted to identify whether JPH2 gene mutation 
contributes to the HCM. Three unique mutations JPH2-T141H, S101R, and S165F were 
first identified from 388 North American HCM referral patients [95]. These probands, 
which had the clear echocardiogram and other diagnosed evidence, were distinct from the 
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mutated genes in sarcomere that were traditionally associated with HCM development. 
Furthermore, the study demonstrated that JPH2-T141H, S101R, and S165F mutations 
were sufficient to induce hypertrophic remodeling in cardiac immortalized cells, along 
with ablated CICR amplitude and disrupted cellular ultrastructure [95]. Additionally, two 
genetic variants JPH2-R436C and G505S have been found in a limited cohort of Japanese 
patients with HCM [96]. However, further studies are required to provide in vitro or in 
vivo evidence to support the pathogenicity of these variants, for the reason that the case 
group was small and the specificity was questioned of these two variants to HCM [96, 
97]. Recently, another JPH2 gene missense mutation annotated as E169K was uncovered 
from an Italian cohort of 203 diagnosed HCM referrals [88]. This mutation was also 
identified to be associated with the development of atrial fibrillation(AF) in a small 
family of HCM probands [88]. Subsequent study on Pseudo-knockin (PKI) mouse 
models expressing E169K mutant, which localized to the structural α-helical domain of 
JPH2, showed a reduced RyR2-JPH2 binding area with increased RyR2-mediated SR 
Ca2+ leak. This alteration disrupted the JMC's stabilization, leading to aberrant 
spontaneous Ca2+ waves and enlarged spark frequency, which as a consequence has a 
higher incidence of induced AF in the mice cardiomyocytes [88]. These results suggest 
that defective JPH2 may be implicated in the development of HCM and disturbance of 
Ca2+ homeostasis in cardiomyocytes.    
1.3.2.2 Role of JPH2 in T-tubule remodeling in failing hearts 
Heart failure refers to the physiological state when cardiac output is no longer sufficient 
to keep up with the required demands of systemic metabolism. This end dysfunction 
stage could be progressively developed from cardiomyopathy, cardiac stress, or other 
chronic factors [98]. It has been demonstrated that severe reduction of myocardial 
contractility attributed to impaired Ca2+ handling is the key characteristic during the 
progression of heart failure and leads to the final cardiac death [99, 100]. 
Many studies have observed T-tubule remodeling, including T-tubule reduction, 
disorganization, and dilation, from different heart failure animal models and human 
patients with heart failure [101-103]. These studies provided compelling evidence that T-
tubule structural remodeling is the key pathological alteration during the progression of 
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many forms of cardiac disease towards heart failure [104, 105]. There is a direct link 
between T-tubule remodeling and dysfunction of SR Ca2+ release [106-108]. Due to the 
structural disorganization of the T-tubule system, the propagation of the action potential 
from the cell surface to T-tubule network experiences some disturbance [109, 110]. Also, 
the structural disorganization state causes T-tubule remodeling to change the distribution 
and organization of the ion carriers resulting in alteration of the shape and the duration of 
action potentials [111-113]. 
As previously mentioned, JPH2 mechanically maintains the structural integrity of T-
tubule/SR coupling and plays an important role in T-tubule development [43, 82]. 
Emerging evidence from recent studies suggest that down-regulation or mislocalization 
of JPH2 contributes to T-tubule remodeling in failing heats. In a transgenic mouse model 
of Gαq-dependent heart failure, JPH2 was cleavage by activated calpain and resulted in 
T-tubule disruption with defect Ca2+ transient. The treatment of calpain inhibitor or 
turning off Gαq prevented calpain-dependent proteolysis of JPH2, and more importantly 
reversed the t-tubule remodeling and the development of heart failure [114]. Moreover, in 
a murine model of pressure overload-induced hypotrophy, the transportation of a kinesin-
driven microtubule densification took part in JPH2 mislocalization, which correlated with 
T-tubule remodeling and led to heart failure [115]. On the other hand, in a transgenic 
mice model, cardiac-specific JPH2 overexpression did not alter the baseline cardiac 
function, but strengthened the T-tubules/junctional SR-coupled dyads, which protected 
the cardiomyocytes from pressure-overload induced T-tubule remodeling and heart 
failure development [116]. This effect was also confirmed by the AAV9-JPH2 mediated 
gene therapy in the transverse aortic constriction (TAC) mouse model. Enhanced JPH2 
ameliorated T-tubule structural disruption and prevented SR Ca2+ leak, which improved 
the contractility of the failing hearts [117]. 
1.4 ER stress and ischemia/reperfusion injury  
The ER/sarcoplasmic reticulum is an organelle involved in many cell functions, including 
the folding of protein molecules, the transport of synthesized proteins to the Golgi 
apparatus, and lipid metabolisms, etc. [118]. ER/sarcoplasmic reticulum is also a major 
storage site of Ca2+  in cells, and can contribute to cellular activities through Ca2+  
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signaling [119]. Ca2+  concentrations within ER/sarcoplasmic reticulum are regulated by 
RyR2 and IP3 receptors which release Ca2+ from the ER/sarcoplasmic reticulum to the 
cytosol, and the sarco/endoplasmic reticulum Ca2+ transport ATPase, which transfers 
Ca2+ from the cytosol to the ER/sarcoplasmic reticulum [120]. 
Ca2+ homeostasis helps maintain normal ER function [121]. Depletion of ER Ca2+ impairs 
the processing and folding of newly synthesized proteins and thus, induces accumulation 
of unfolded proteins, leading to ER stress [122]. This stress triggers the unfolded protein 
response (UPR) which activates ER transmembrane sensors to initiate the adaptive 
responses [123]. The three well-described ER transmembrane sensors include protein 
kinase-like ER kinase (PERK), inositol-requiring kinase 1 (IRE1), and activating 
transcription factor 6 (ATF6) [124, 125]. Activation of the PERK pathway results in 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α), global translation 
attenuation, and subsequent translation of the transcription factor ATF4 [126, 127]. IRE1 
activation leads to JNK1/2 activation and transcriptional induction and splicing of XBP-1 
[128, 129]. Proteolysis of ATF6 facilitates its nuclear translocation and subsequent 
transcriptional action [130, 131]. In concert, these pathways lead to the induction of 
genes including chaperones GRP78 and GRP94, XBP1 and CHOP. If ER stress is 
prolonged or overwhelming, however, it can induce cell death mainly through the 
activation of JNK1/2, CHOP and caspase-12 pathways [132]. Many studies have reported 
the activation of ER stress in the ischemic heart [56, 125]. However, the role of ER stress 
in the ischemic myocardium is complex and controversial. Either ischemia or 
ischemia/reperfusion can potentially induce the adaptive and pro-apoptotic pathways of 
UPR. 
Martindale et al. have demonstrated the activation of the ATF6 branch of ER stress and 
its protective effect in the heart against I/R injury [133]. In their study, transgenic mice 
with tamoxifen-activated ATF6 exhibit better myocardium recovery from ex vivo I/R, 
compared to the non-tamoxifen-treated mice hearts. They also found that the acute 
activation of ATF6 in cardiomyocytes significantly reduced necrosis and apoptosis, along 
with increased cytoprotective ER-resident chaperones, including GRP78 and GRP94 
[133].The cardioprotective role of the ATF6 arm was supported by another study where 
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the inhibition of ATF6 in mice using 4-(2-aminoethyl) benzenesulfonyl fluoride further 
developed cardiac remodeling in ischemic heart and cause higher mortality rate [134]. 
Another effector of the UPR that preserves the myocardium against ischemic injury is the 
transcription factor X-box binding protein-1 (XBP1). Thuerauf et al., in their study using 
rat neonatal cultured cardiomyocytes, showed that hypoxia increased XBP1 mRNA 
splicing, as well as the expression of other UPR markers [135]. They infected the cells 
with a recombinant adenovirus encoding dominant-negative XBP1 and then subjected it 
to hypoxia/reoxygenation. Inhibition of XBP1 sharply increased H/R-induced apoptosis, 
demonstrating the cardioprotective role of the XBP1 arm against I/R injury [135]. 
Furthermore, GRP94, which is one of the cytoprotective chaperones, is up-regulated by 
XBP1 during ER stress [136, 137]. Overexpression of GRP94 in cultured H9c2 
cardiomyocytes significantly reduced the necrosis caused by calcium overload or 
simulated ischemia, indicating that the XBP1-inducible proteins may contribute to the 
protective effect [138]. 
On the other hand, the pro-apoptotic effect of ER stress has also been demonstrated in the 
ischemic heart. Terai et al. showed that hypoxia induced CHOP expression and the 
cleavage of caspase-12 in neonatal rat cardiomyocytes [139]. In their study, they found a 
significantly reduced apoptosis rate after the inhibition of these two ER stress-specific 
apoptotic pathways by the small interfering RNA (siRNA) technique. Thus, ER-initiated 
apoptotic signaling is involved in cell death after a hypoxic insult [139]. Furthermore, 
Tao et al. reported the ER stress-dependent apoptosis in vivo rat I/R model, as evidenced 
by increased CHOP, caspase-12, and JNK activation [140]. Modification of ER stress by 
apelin infusion, which significantly attenuated the activation of all the three pro-apoptotic 
pathways, successfully reduced the caspase-3 activity (apoptosis marker) and the final 
infarct size after reperfusion [140]. In addition, the p53-upregulated modulator of 
apoptosis (PUMA), which is a pro-apoptotic member of the Bcl2 family, has been 
implicated in ER stress-dependent cardiomyocyte apoptosis. Nickson et al. reported that 
the pharmacological stressor-induced ER stress promoted the expression of PUMA in 
neonatal cardiomyocytes and increased apoptosis [141]. In Langendorff-perfused isolated 
mice hearts, the targeted deletion of PUMA improved cardiac function and protects 
cardiomyocytes from cell death during I/R periods [142]. 
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The mechanisms of I/R-induced pro-apoptotic ER stress remain unclear, especially when 
oxygen and nutrients are restored after reperfusion. Disrupted intracellular Ca2+ 
homeostasis may play a fundamental role in it. Emerging evidence suggested that not 
only the depletion of Ca2+ in ER but also the concomitant Ca2+ elevation in cytosol 
contributes to the activation of pro-apoptotic ER stress events [123, 143]. Thus, the 
correction of I/R-induced aberrant Ca2+ release from SR/ER may prevent pro-survival ER 
stress shifting into pro-apoptotic. ER stress may represent an important therapeutic target 
for I/R injury and ischemic heart diseases. 
1.5 Calpain/calpastatin system in ischemic heart  
Calpains belong to a family of Ca2+-dependent cysteine proteases. Fifteen isoforms have 
been reported in mammals. Among them, calpain-1 (µ-form) and calpain-2 (m-form) are 
ubiquitously expressed in the cytoplasm, and other calpain family members have more 
limited tissue distribution [144]. Calpain-1 and calpain-2 are heterodimers, differing in 
their Ca2+ requirement for activation (~50 µM for calpain-1 and ~1000 µM for calpain-2) 
[145]. They consist of a distinct large 80-kDa catalytic subunit encoded by the genes 
capn1 and capn2, respectively, and a common small 28-kDa regulatory subunit encoded 
by capn4, also known as capns1 [146]. The small subunit is indispensable for calpain-1 
and calpain-2 assembly and activation [147]. Thus, deletion of capn4 functionally knocks 
out calpain-1 and calpain-2 [148]. Both calpain-1 and calpain-2 are tightly regulated by 
the intracellular free Ca2+ [149]. They are also controlled by its endogenous inhibitor 
calpastatin. Calpastatin specifically inhibits calpain-1 and calpain-2, but not other 
cysteine proteases [150]. 
Accumulative evidence has suggested that calpain activation plays a critical role in 
ischemic heart diseases. The proteolytic activity of calpain during I/R targets α-fodrin, 
which is a crucial component to the formation of a membrane's cytoskeleton [151]. 
Evidence indicated that the degradation of α-fodrin increased the fragility of the 
sarcolemma [152, 153]. In cultured cardiomyocytes, the activation of calpain cleaved 
fodrin into two fragments of 150 and 145 kDa [154]. Immunohistochemical studies 
further confirmed this proteolysis that occurred at the sarcolemma and the intercalated 
discs following I/R in rat hearts [155]. In vivo administration of calpain inhibitor-1 in 15-
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minute global ischemia and 60-minute reperfusion rat hearts successfully suppressed the 
degradation of α-fodrin and prevented I/R-induced contractile dysfunction [156]. In 
another rat model with transient coronary occlusion, the intravenous infusion of calpain 
inhibitor-3 (MDL-28170) during the first minute of reperfusion preserved α-fodrin 
degradation and reduced the final infarct size by 32% [157]. It has been implied that the 
degradation of this membrane's backbone could lead to disruptions on ion channels [158]. 
L-type Ca2+ channels (LTCC) are the indispensable membrane's signal transporters that 
conduct excitation-contraction coupling in cardiomyocytes [36]. Decreased activities of 
LTCC have been reported upon the disturbance of cytoskeletal proteins [155]. Calpain 
inhibitor-3 counteracted the proteolysis of LTCC in I/R-injured cardiomyocytes [159]. 
Moreover, a novel calpain inhibitor, SNJ-1945, has been shown to prevent I/R-induced α-
fodrin degradation and restore the total Ca2+ handling in excitation-contraction coupling 
[160]. These together indicated a possible regulating role of α-fodrin to the basal activity 
of LTCC. Another ion channel that was affected by the degradation of α-fodrin is 
Na+/K+-ATPase. It has been demonstrated that Na+/K+-ATPase binds to the fodrin-based 
membrane cytoskeleton through the sarcolemmal protein ankyrin [161]. An in-vitro study 
on isolated cardiomyocytes from rats identified the calpain activation that proteolyzed 
both α-fodrin and ankyrin at the beginning of reperfusion. The α-subunit of the Na+/K+-
ATPase was found to be detached from its membrane anchorage, which resulted in the 
failure interaction of this channel [162]. The loss of the Na+-pump compromises the 
normalization of cytosolic Na+ concentration at the onset of reperfusion and results in the 
further disruption of Ca2+ homeostasis [163]. Inhibition of calpain with MDL-28170 
during reperfusion increased Na+/K+-ATPase activity and improved contractile recovery 
[162]. 
On the other hand, I/R-induced calpain proteolysis also disrupts Ca2+ handling by directly 
targeting key Ca2+ channels [164]. SERCA2a is an essential Ca2+-ATPase that reuptakes 
Ca2+ from cytosol to the lumen of SR/ER [48]. Its dysregulation impairs SR-mediated 
cardiac contractile function [165]. I/R-induced calpain activation has been demonstrated 
to degrade SERCA 2a and the SERCA regulatory protein PLB in perfused rat hearts 
[164]. Calpain inhibition with calpain inhibitor-3 (MDL-28170) during I/R attenuated the 
degradation of both proteins and improved the cardiac contractility [166]. This was 
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supported by another study on langedorff-perfused rat hearts, which were subjected to I/R 
in the presence and absence of calpain inhibitor: leupeptin. The presented data suggested 
that I/R-induced calpain activation was not only responsible for the degradation of 
SERCA2a but also for the cleavage of raynodine receptor-2 (RyR2), the major Ca2+ 
release channel on SR. Treatment with leupeptin recovered SR function and regulation, 
which was consistent with improved cardiac contraction after I/R [167]. 
Furthermore, the damage of mitochondria during I/R has also been associated with 
calpain activation. In a model of Langendorff-perfused isolated rabbit hearts, Sonata et al 
using the skinned fiber technique, observed decreased state 3 reparation rate (a parameter 
of mitochondrial function) after global ischemia and reperfusion [168]. Reduced state 3 
respiration reflects the impairment of all complex I in the electron transport chain (ETC) 
[169]. They showed that calpain inhibition (BSF 409425) significantly improved state 3 
reparation, so for the first time, it involved calpain activation in I/R-caused mitochondrial 
injuries [168]. This was also supported by [170]. Treatment with either calpain inhibitor 
BSF 409425 or A-705239 also attenuated mitochondrial leak-respiration and state 4 
respiration, which provided evidence that calpain inhibition could prevent the inner 
mitochondrial membrane from becoming permeable [168, 170]. Thus, the proteolytic 
activity of calpain can function as a cytolytic initiator for the mitochondrial permeability 
transition during I/R. 
In addition to cytosol, calpains and their endogenous inhibitor, calpastatin, have also been 
reported that present in mitochondria [171]. It is believed that I/R-induced intracellular 
Ca2+ overload forced excessive Ca2+ influx into the mitochondria and triggered the 
activation of mitochondrial calpains [172]. One of the most serious consequences of the 
activation of mitochondrial calpain is the cleavage and release of the apoptosis inducing 
factor (AIF) [173]. AIF is a mitochondrial antioxidant that is mostly located within the 
mitochondrial intermembrane space [174]. It has been demonstrated that AIF could be 
released into cytosol to induce caspase-independent apoptotic cell death under stress 
circumstances [175]. However, before release from mitochndria, it requires the cleavage 
of its anchored site on the inner membrane [176]. Qun Chen et al. first identified that μ-
calpain presented in isolated and purified cardiac mitochondria. In this study, global I/R 
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on Langendorff-perfused mouse hearts triggered the activation of mito-μ-calpain and 
decreased AIF content in the isolated mitochondria [177]. Calpain inhibitor MDL-28170 
preserved the AIF content within mitochondria, indicating the required role of mito-μ-
calpain in AIF cleavage. Calpain inhibition also decreased myocardial injury during I/R, 
as reflected by the decreased LDH release when compared to untreated hearts [177]. 
Thus, they provided evidence that mitochondrial μ-calpain contributed to I/R injury in 
cardiomyocytes by its proteolytic effect on AIF. 
Recently, we discovered a novel pathway linking calpain activation to I/R-induced lethal 
injury in cardiomyocytes that involved the induction of ER stress and subsequent JNK1/2 
activation [178]. Indeed, we found that ER stress and apoptosis could be directly induced 
by only up-regulation of calpain-1 in cultured cardiomyocytes, indicating the correlation 
between them. Inhibition of calpain-1 prevented the induction of ER stress, and JNK1/2 
activation in hypoxia/reoxygenation (H/R) stimulated cardiomyocytes [178]. Importantly, 
it was also demonstrated that ER stress/JNK1/2 signaling mediates apoptosis in 
cardiomyocytes following H/R. Inhibition of ER stress protected cardiomyocytes against 
H/R- or calpain-1-induced apoptotic cell death [178]. In vivo, transgenic mice with 
overexpression of calpastatin (Tg-CAST) significantly attenuated ER stress and 
phosphorylated JNK1/2 after I/R, confirming the important role of calpain activation in 
ER stress-mediated apoptosis [178]. Thus, calpains have become attractive targets for the 
development of synthetic inhibitors for therapy to reduce I/R injury and ischemic heart 
disease.  
1.6 Rationale 
Myocardial infarction (MI) is a fatal ischemic heart disease and a leading cause of death 
in Canada [2]. Reperfusion remains the primary and effective therapy. However, 
reperfusion can induce damage to the ischemic myocardium, a condition described as 
ischemia/reperfusion (I/R) injury, which contributes to heart failure post MI [4, 19]. Over 
500,000 Canadians are afflicted with heart failure, and up to 50% of them die within five 
years of diagnosis [18]. Unfortunately, effectively limiting myocardial I/R injury remains 
a major challenge and is in urgent need for further investigation. 
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Our lab has recently demonstrated an important role for calpain activation in myocardial 
I/R injury and MI [178]. We further reported that calpain cleaved and down-regulated 
junctophilin-2 (JPH2) protein in hearts following I/R [179]. These findings raise an 
intriguing question: does decreased JPH2 contribute to myocardial I/R injury? 
JPH2 plays a role in modulating the gating of RyR2 Ca2+ channel, preventing aberrant 
Ca2+ release via RyR2 in cardiomyocytes and thus, ensuring appropriate Ca2+ 
homeostasis [89, 180]. Importantly, Ca2+ homeostasis is disrupted in cardiomyocytes 
during I/R [59, 62]. It is known that perturbation of Ca2+ homeostasis results in the 
activation of downstream Ca2+ signaling, in particular calpain activation [151, 181]. Our 
lab reported that calpain activation induces ER stress in cardiomyocytes [178]. ER stress 
has been demonstrated to contribute to apoptosis in cardiomyocytes under stress [55, 
132]. Thus, we reason that decreased JPH2 promotes cardiomyocyte I/R injury. 
Understanding the role of JPH2 in myocardial I/R injury is clinically relevant because the 
protein levels of JPH2 are reduced in human diseased hearts [77, 94]. Thus, this study 
will help to identify therapeutic targets which may inform a future clinical trial of 
pharmacological approaches in patients with ischemic heart disease, with the goal of 
improved clinical outcomes in human ischemic heart disease. 
1.7  Hypothesis 
I/R induces down-regulation of JPH2 in cardiomyocytes. Decreased JPH2 promotes 
RyR2 dysfunction and perturbation of Ca2+ homeostasis, which triggers calpain 
activation and ER stress, leading to apoptosis in cardiomyocytes. Up-regulation of JPH2 
prevents Ca2+ dysregulation and protects cardiomyocytes from apoptosis following I/R. 
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Chapter 2  
2 Materials and Methods 
2.1 Cell culture 
H9c2 cells were purchased from the American Type Culture Collection (ATCC)，and 
were employed within 10 generations for this study. H9c2 is a subclone of the original 
clonal cell line derived from embryonic BD1X rat heart tissue. The cells were grown in a 
culture flask at 37 °C in a 5% CO2 humidified incubator, and maintained in Dulbecco's 
modified Eagle's medium (DMEM, Invitrogen, Chicago, IL, USA) which was 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin 100 IU/mL, 
and streptomycin 10 µg/mL (Invitrogen, Chicago, IL, USA). Cultured H9c2 cells were 
split every three days. To passage the H9c2 cells, media was aspirated; cells were washed 
with D-Hank's solution (NaCl, KCl, KH2PO4, NaHCO3, D-glucose, phenol red), and 
incubated with 0.25% Trypsin (Gibco, Life Technologies Burlington, ON, Canada) at 
room temperature for 20 to 30 seconds. Fresh culture media was added to terminate the 
trypsinization process, and cells were divided and re-plated as required. 
2.2 Neonatal mouse cardiomyocyte isolation 
Primary cardiomyocytes were isolated from neonatal mice born within 2 days. Briefly, 
after sterilizing using 70% ethanol, the neonatal mice's hearts were harvested and placed 
into D-Hank's solution (50 mL tube). Each heart was cut into 4–5 pieces using a surgical 
blade, and washed using D-Hank's solution. The heart pieces were then subjected to the 
following 3 rounds of digestion: (1) Heart tissues were incubated with 2 mL Liberase 
Blendzyme(10μg/mL) in a water bath at 37°C for 10 min. After stirring 3-5 times, the 
supernatant was discarded; (2) The tissues were incubated with 4 mL of fresh Liberase 
Blendzyme solution at 37°C. During the incubation, the minced hearts were gently 
swirled in every 5 minutes. After 15 minutes, the supernatant was collected and stored in 
DMEM containing 10% FBS (Invitrogen, Chicago, IL, USA); (3) Four mL of fresh 
Liberase Blendzyme solution were added into the heart tissues. The digestion was 
followed as described in (2). The supernatants from (2) and (3) were pooled and 
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centrifuged at 200g for 5 min. The resulting cell pellets were re-suspended in DMEM 
containing 10% FBS. Next, the suspended cells were subjected to pre-plating in a culture 
dish containing 6 mL of DMEM containing10% FBS at 37°C for 120 min. The pre-
plating allowed fibroblasts to adhere to the culture plate. After fibroblast adherence, 
cardiomyocytes were collected, and the cell number was counted. The cardiomyocytes 
were then seeded into a culture plate which has been already paved with 1% gelatin for 
120 min in an incubator. Finally, the plate containing cardiomyocytes was placed in a 
CO2 incubator at 37°C. After 18 hours, the cardiomyocytes were subjected to various 
experiments. 
2.3 Adenoviral infection 
Cultured H9c2 cells or primary neonatal mice cardiomyocytes were infected with 
recombinant adenoviral vectors containing human JPH2 (Ad-JPH2) or beta-gal (Ad-gal) 
as a control at a multiplicity of infection (MOI) of 100 plaque forming units per cell (100 
PFU/cell). These adenoviral vectors were purchased from Vector Biolabs (USA). The 
adenoviral vectors were prepared in DMEN with 2% FBS and added to the cells in half 
the volume of cultural medium. After incubation for 2 h, the full volume of culture 
medium was supplied. All experiments were implemented after 24 h of adenoviral 
infection. 
2.4 Hypoxia/reoxygenation (H/R) 
For the induction of hypoxia, cardiomyocytes were placed in the plates, and the culture 
medium was reduced to half volume. Next, cardiomyocytes were placed in a sealed bag 
containing GENbag anaer (bioMérieux) at 37 °C for 24 h. A indicator (bioMérieux) was 
used to monitor hypoxia. Inside the bag containing the GENbag anaer, the O2 
concentration was rapidly reduced close to zero within 30 min. This experimental 
condition perfectly mimics the initial period of ischemia. Reoxygenation was achieved by 
replacing culture media with fresh one and returning the cells to normal culture 
conditions. 
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2.5 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blot analysis 
Cells were lysed in a lysis buffer containing 1% Triton-X-100, 0.5 mM EDTA, 15 mM 
NaCl, and 2 mM Tris base (Invitrogen, Chicago, IL, USA). The cell lysates were then 
collected and centrifuged at 10,000g at 4°Cfor 10 min. After that, the supernatant was 
transferred into a clean tube, and the protein concentration was determined by the 
Bradford assay. The gel casting apparatus was assembled first with 1.5 mm spacers, and 
was tested for leaks to implement the SDS-PAGE. A concentration of 10% or 12% of 
separating gel was then prepared, depending on the size of the target protein in the 
sample [Table 1, For a 10mL separating gel]. 
Table 1:Composition of separating gel 
Acrylamide percentage 12% 15% 
H2O 3.2 mL 2.2 mL 
Acrylamide/Bis-acrylamide 
(30%/0.8% w/v) 
4 mL 5 mL 
1.5M Tris(pH=8.8) 2.6 mL 2.6 mL 
10% (w/v) SDS 0.1 mL 0.1 mL 
10% (w/v) ammonium 
persulfate (AP) 
100 μL 100 μL 
TEMED 10 μL 10 μL 
 
The mixture was then immediately transferred to the casting apparatus, with a water 
overlay to avoid the air interference. After the separating gel was solidified in 15-20 
minutes, the stacking gel was made [Table 2, For a 5 mL stacking gel] and filled on top 
of the separating gel. A clean 10 wells comb was inserted to make sure that no residual 
bubbles were in the wells. 
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Table 2: Composition of stacking gel 
 
 
 
 
 
 
 
 
 
 
A total of 50 μg proteins from sample lysates were mixed with the loading buffer [Table 
3, for a 10 mL Laemmli buffer 6X] (the volume ratio of 5:1). The sample mixtures were 
boiled at 95°C for 5 min and loaded into wells using gel loading tips. The gel assembly 
was taken out of the casting and put into the gel tank. Running buffer (0.025 M Tris base, 
0.192 M Glycine, 0.1 % SDS) was then poured into the tank until above the top of the gel 
(~800 mL). 
Table 3: Composition of loading buffer 
 
 
 
 
 
 
H2O 2.975 mL 
0.5 M Tris-HCl, pH 6.8 1.25 mL 
10% (w/v) SDS 0.05 mL 
Acrylamide/Bis-acrylamide 
(30%/0.8% w/v) 
0.67 mL 
10% (w/v) ammonium 
persulfate (AP) 
0.05 mL 
TEMED 0.005 mL 
ddH2O 2.10 mL 
0.5 M Tris-HCl, pH 6.8 1.20 mL 
SDS 1.20 g 
Bromophenol blue 6.00 g 
Glycerol 4.70 mL 
DTT 0.93 g 
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Next, the electrophoresis assembly was connected to the power supply set at 15mA, 
200V, and 24W for about 1 hour or until the running front reached the end of the gel. 
After electrophoresis, proteins were separated and transferred to a polyvinyl difluoride 
(PVDF) membrane as follows:  First, the PVDF membrane and the transfer cassette 
equipment was immersed in transfer buffer (20% v/v methanol, 0.19 M glycine, and 0.05 
M Tris);  Next, the cassettes were assembled in a layer of blotting paper, a sponge, PVDF 
membrane, electrophoresed gel, blotting paper, and a sponge; The cassette was then 
placed in the tank filled with transfer buffer at 30V in the fridge (4°C) for overnight.  
In the next day, PVDF membranes were taken out from the cassette and kept with 5% 
non-fat milk in tris-buffered saline containing Tween 20 (TBST) at room temperature for 
one hour. This step was to block the non-specific binding sites. Following this, primary 
antibodies were diluted with 5% BSA (5ml), and applied to the membranes in a clean 
tube. The tube was then set on a rocking table and subjected to 4°C for overnight. After 
being incubated with primary antibodies, PVDF membranes were washed three times 
with TBST, with 10 minutes for each time. The membranes were then incubated with 
secondary antibodies in 5% non-fat milk at room temperature for one hour. Following 
incubation, the washing step was repeated again in TBST for three times, with10 minutes 
each time. Finally, the membranes were immersed in ECL reagent for one minute. The 
signals were visualized using an enhanced chemiluminescence-detection system. 
2.6 Caspase-3 activity measurement 
Activated caspase-3 in cardiomyocytes was measured using a caspase-3 activity assay kit 
according to the manufacturer's protocol (BIOMOL Research Laboratories). Lysis buffer 
containing 50 mM HEPES (pH 7.4), 0.1% CHAPS, 5 mM DTT, 0.1 mM EDTA and 
0.1% NP-40 (Invitrogen, Chicago, IL, USA) was added to cardiomyocytes. Cell lysates 
were collected and centrifuged at 10,000g at 4°C for 10 minutes. Then, the supernatant 
was transferred into a clean tube, and the protein concentration was determined by the 
Bradford assay. A total of 50μg protein was incubated with caspase-3 substrate Ac-
DEVD-AMC or Ac-DEVD-AMC in the presence or absence of inhibitor AC-DEVD-
CHO diluted in assay buffer at 37°C for 2 hours. The assay buffer contained 50 mM 
HEPES (pH 7.4), 0.1% CHAPS,10 mM DTT, 1 mM EDTA,10 mM NaCl, and 10% 
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Glycerol. Caspase-3 targeted chromophore AMC and cleaved it from the peptide 
substrate's C-terminus. The fluorescence intensity of cleaved AMC was quantified by a 
fluorescent spectrophotometer with excitation 355 nm/emission 460 nm. 
2.7 Cellular DNA fragmentation 
DNA fragmentation was measured using a Cellular DNA Fragmentation ELISA kit 
(Roche Applied Science, Canada) according the manufacturer’s instructions.H9c2 cells 
were pre-labeled with BrdU. After various treatments, cells were lysed and cell lysates 
were collected. After centrifuged at 250 g at 4 °C for 10 min, the supernatant was 
transferred to a clean tube, and the protein concentration was determined by the Bradford 
assay. A 96-well microplate was pre-coated with anti-DNA antibody at 4°C for 
overnight. The following day, incubation buffer was added to each sample well. The plate 
was left at room temperature for 30 minutes. After three washes of the pre-coated 
microplate with the washing buffer, samples were added into the microplate and stranded 
for 90 minutes at room temperature. This step allowed the BrdU-labeled DNA fragments 
to bind to the immobilized anti-DNA antibody. Next, the samples in the microplate were 
washed twice. For the third wash, the microplate with washing buffer was placed in a 
microwave for 5 minutes, followed by 10 minutes at -20 °C. BrdU-labeled DNA 
fragments were denatured and fixed on the bottom of the microplate in this step. In the 
next step, second-antibody anti-BrdU-peroxidase diluted in washing buffer was placed 
into each sample well of the microplate and stranded at room temperature for 90 minutes. 
Finally, 100 μL TMB substrate was added to each well, and the fluorescence intensity of 
peroxidase bound in the immune complex was determined by a fluorescent 
spectrophotometer with excitation of 355 nm/emission of 450 nm. Results were 
expressed as fold increases over control. 
2.8 Calpain activity 
Cells were lysed in a lysis buffer containing 20 mM Tris-HCL (pH 7.6),150 mM NaCl, 
and 1% Triton X-100 (Invitrogen, Chicago, IL, USA). Cell lysates were then subjected to 
sanitation on ice for 10 seconds and centrifuged at 11,000g at 4°C for 10 min. The 
supernatant was transferred into a clean tube, and the protein concentration was 
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determined by the Bradford assay. A total of 30μg proteins were incubated with a 
fluorescence substrate N-succinyl-LLVY-AMC (Cedarlane Laboratories) diluted in 
reaction buffer (63 mM imidazole–HCl, pH 7.3, 10 mM β-mercaptoethanol, 1 mM 
EDTA, and 10 mM EGTA) with or without calcium chloride at 37 C ° for 2 h. The 
fluorescence intensity of cleaved AMC was quantified with a multilabel reader 
(excitation, 360 nm; emission, 460 nm), and calpain activity was determined as the 
difference between calcium-dependent and calcium-independent fluorescence. 
2.9 Single cell calcium photometry and SR leak 
Cells were plated on the surface of a 35 mm glass coverslip within each well of a 24-well 
plate. On the experiment day, cells were loaded with 2μM fura-2 AM (Invitrogen, 
Chicago, IL, USA) at 37 °C in a 5% CO2 humidified incubator for 40 min. Cells were 
then washed twice and replaced with 500μL normal Tyrode (NT, 140 mM NaCl,4 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 5 mM HEPES, pH 7.4) and stood 
at 37 °C for additional 10 min. For the experiment, the glass coverslip with attached cells 
was placed in a perfusion chamber. 1mL of extracellular buffer NT was provided to the 
chamber. Fluorescence intensity at 510 nm was measured with alternating 345 nm and 
380 nm excitation (Ratio F345/380), by a Deltascan monochrometer system (Photon 
Technology International, London, ON). Only one cell was tested from each coverslip. 
After a steady state of the ratio intensity, SERCA inhibitor 10 μM cyclopiazonic acid 
(CPA) was slowly added to the bath by a pipette (close but not inserted into the surface of 
the medium). The increased intracellular Ca2+ was measured and taken to analyze the SR 
leak. For the negative control, RyR2 inhibitor 3μM tetracaine (Invitrogen, Chicago, IL, 
USA) was administrated with NT before testing. 
2.10 Statistical Analysis 
All data were presented as mean ± standard deviation (SD). Results were analyzed by 
two-way ANOVA followed by the Newman-Keuls test for multi-group comparisons. A 
student ‘s T-test was adopted for comparison between 2 groups. The value P < 0.05 was 
considered statistically significant. 
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Chapter 3  
3 Results 
3.1 Establishment of an in vitro model of 
Hypoxia/Reoxygenation injury 
The in vitro experimental model of hypoxia/reoxygenation (H/R) in cultured 
cardiomyocytes has been widely used to mimic in vivo ischemia/reperfusion in the heart 
[182]. The H/R was induced as described in Method chapter. To confirm the hypoxic 
conditions, we added 300 μL of culture media to each well in 24-well plate and measured 
O2 concentration in culture media at different time points after hypoxia. This volume of 
culture media was chosen because the same volume of culture media was used for cell 
culture during H/R. As shown in Table 4, the O2 concentration was dramatically reduced 
by up to 50% within 30 min and by greater than 80% after 6 hours. It is important to 
mention that the actual O2 concentration was lower after hypoxia because the culture 
media was exposed to normal air for a while before O2 measurement. This result verifies 
the hypoxic conditions in culture media. 
Table 4: O2 concentration in different time points after hypoxia 
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We next determined whether this H/R condition was sufficient to induce apoptosis in 
cardiomyocytes. To do this, we seeded H9c2 cells into 24-well plates. Twenty-four hours 
later, we exposed the cells to a hypoxic condition for 24 hours followed by reoxygenation 
for additional 24 hours. H9c2 cells were then assayed for caspase-3 activity, which is the 
most frequently activated death protease in the execution phase of apoptosis. H/R 
significantly increased the level of caspase-3 activity by one fold compared to the control 
group under normoxic condition (N/R group) [Figure 4A]. Apoptosis was further 
analyzed by measuring DNA fragmentation, which is also a biological hallmark of 
apoptosis. Similarly, H/R increased DNA fragmentation by one fold in comparison to the 
N/R group [Figure 4B]. These results demonstrate that H/R induces apoptosis in H9c2 
cells, indicative of cell injury. Taken together, we successfully establish an in vitro model 
of H/R-induced injury in cardiomyocytes, which was employed for the following studies.  
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Figure 4: Assessments of apoptosis on H9c2 cells following H/R 
H9c2 cells were subjected to 24h hypoxia, followed by 24h reoxygenation. Apoptosis 
was assessed by (A) measuring caspase-3 activity, and (B) DNA fragmentation. Data are 
normalized to control and expressed as means ± SD from at least 3 different experiments. 
*p <0.05 analyzed by unpaired student’s T-test. 
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3.2 H/R down-regulated JPH2 protein expression in 
cardiomyocytes 
JPH2 is down-regulated in diseased hearts [77, 117]. We determined whether H/R 
decreased JPH2 protein expression in cardiomyocytes. At different time points after 
reoxygenation, we examined the protein levels of JPH2 by western blot analysis. Our 
result showed that the protein levels of JPH2 were reduced after hypoxia and further 
decreased during early reoxygenation within 3 hours. The protein levels of JPH2 were 
increased a little after 3 hours during reoxygenation but remained lower than those before 
H/R [Figure 5]. In contrast, the protein levels of GAPDH were not changed after H/R. 
This data demonstrates that H/R induces down-regulation of JPH2 protein in 
cardiomyocytes. 
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Figure 5: Time course of JPH2 protein expression following H/R in H9c2 cells 
H9c2 cells were subjected to hypoxia for 24h, and were analyzed for JPH2 and GAPDH 
protein expression at different time points after reoxygenation. (A) A western blot for 
JPH2 and GAPDH protein expression from 1 experiment (not replicated). (B) 
Quantification of JPH2 protein expression relative to GAPDH. 
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3.3 Adenoviral vector mediated up-regulation of JPH2 
expression in heart cells 
To up-regulate JPH2 protein expression in cardiomyocytes, we infected H9c2 cells with 
adenoviral vectors containing human JPH2 gene (Ad-JPH2) or beta-gal (Ad-gal) as a 
control at a multiplicity of infection (MOI) of 100 plague forming units (PFU) per cell. 
Twenty-four hour after adenoviral infection, western blot analysis was performed to 
determine the protein levels of JPH2 and GAPDH [Figure 6]. The protein levels of JPH2 
increased significantly in Ad-JPH2 infected H9c2 cells, compared to Ad-gal group. These 
results indicate that infection with Ad-JPH2 induces up-regulation of JPH2 protein 
expression in H9c2 cells.  
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Figure 6: JPH2 protein expression in Ad-JPH2 infected H9c2 cells 
H9c2 cells were infected with Ad-JPH2 or Ad-gal. (A) A representative western blot for 
JPH2 and GAPDH from three different experiments. (B) Quantification of JPH2 protein 
expression relative to GAPDH. Data are mean ± SD from 3 different experiments. 
*P < 0.05 analyzed by unpaired student’s T-test. 
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3.4 Up-regulation of JPH2 prevented apoptosis 
induced by H/R 
To determine the role of JPH2 in H/R-induced apoptosis, we infected H9c2 cells with 
Ad-JPH2 or Ad-gal as a control. Twenty-four hours later, the cells were subjected into 
H/R or N/R. After 24 hours reoxygenation, apoptosis was determined by measuring 
caspase-3 activity and DNA fragmentation. As shown in Figure 7, H/R significantly 
increased caspase-3 activity and DNA fragmentation, indicative of apoptotic cell death. 
This effect of H/R on apoptosis was prevented by infection with Ad-JPH2. These results 
demonstrate that up-regulation of JPH2 protects cardiomyocytes against H/R-induced 
apoptosis. 
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Figure 7: Effect of JPH2 up-regulation on apoptosis in H9c2 cells after H/R 
H9c2 cells were infected with Ad-JPH2 or Ad-gal, and then subjected to H/R. Apoptosis 
was assessed by measuring caspase-3 activity (A) and DNA fragmentation(B). Data are 
mean ± SD from 3 different experiments. *P < 0.05 and #P < 0.05 analyzed by two-way 
ANOVA followed by the Newman-Keuls test. 
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3.5 JPH2 regulated RyR2-mediated aberrant Ca2+ 
release from SR in H/R-stimulated cardiomyocytes. 
SR Ca2+ leak has been implicated in ischemic heart disease [100, 180]. Recent studies 
suggested that JPH2 is a negative regulator of RyR2 gating [86, 89]. We investigated 
whether JPH2 regulated aberrant Ca2+ release from SR via RyR2. Sarcoplasmic reticulum 
calcium-ATPase (SERCA) is a major cytosolic Ca2+efflux channel that reuptakes Ca2+ to 
SR/ER. Its inhibition disrupted the dynamic balance of Ca2+ cycling, leading to 
temporary Ca2+ accumulation in cytosol. In the H9c2 cells under N/R, intracellular Ca2+ 
level gradually increased after inhibition of SERCA by cyclopiazonic acid (CPA,10uM) 
[Figure 8]. However, compared to N/R, H/R enhanced intracellular Ca2+ level in cytosol 
after incubation with CPA. This result suggests that H/R may promote Ca2+ release from 
SR. To confirm this, we blocked RyR2 with its antagonist tetracaine (3uM) in H9c2 cells 
and then added CPA. As shown in Figure 8, the rising Ca2+ in H/R-stimulated H9c2 cells 
was prevented and the levels were even lower than that in N/R group, supporting that the 
CPA-induced Ca2+ cytosolic Ca2+ influx is from SR via RyR2. This result also eliminated 
the possibility that extracellular Ca2+ or Ca2+ stored in other organelle like mitochondria 
got involved in the CPA-stimulated intracellular Ca2+ inflow. Taken together, these 
results indicate that H/R impairs RyR2 function and subsequently induces aberrant Ca2+ 
release from SR. 
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Figure 8: Measurement of SR Ca2+ release in H9c2 cells following H/R 
After 24h hypoxia followed by 24h reoxygenation, H9c2 cells were loaded with Fura-2 
AM (2μM) and shifted in normal Tyrode(NT) medium. Intracellular Ca2+ changes were 
assessed by Delta Scan digital fluorescence photometry. (A) Representative Fura-2 ratio 
illustrating cytosolic Ca2+ changes after administration of CPA in three different samples, 
which are normoxia, H/R and tetracaine pretreated H/R. (B) Quantification of increased 
Ca2+ ratio in cytosol after administration of CPA. Data are means ± SD of 11-16 cells for 
each condition from more than three independent preparations, *p < 0.05 and **p<0.05 
analyzed by two-way ANOVA followed by the Newman-Keuls test. 
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To determine whether JPH2 regulated H/R-induced aberrant SR Ca2+ release via RyR2, 
we infected H9c2 cells with Ad-JPH2 or Ad-gal as a control. Twenty-four hours after 
adenoviral infection, the cells were subjected into H/R. CPA-stimulated Ca2+ elevation 
was measured thereafter. Infection with Ad-JPH2 prevented RyR2-mediated abnormal 
Ca2+ efflux from SR [Figure 9]. Thus, up-regulation of JPH2 normalizes Ca2+ regulation 
in cardiomyocytes. 
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Figure 9: Effects of JPH2 up-regulation on aberrant SR Ca2+ release in H9c2 cells 
following H/R 
H9c2 cells were infected with Ad-JPH2 or Ad-gal, and then subjected to a 24-hour 
hypoxia followed by a 24-hour reoxygenation. Cells were then loaded with Fura-2 AM (2 
μM) and shifted in normal Tyrode(NT) medium. (A) Representative Fura-2 ratio 
illustrating cytosolic Ca2+changes after administration of CPA in H/R group. (B) 
Quantification of increased Ca2+ ratio in cytosol after administration of CPA in H/R 
group. Data are means ± SD from at least three independent preparations with 10-14 cells 
for each condition. *p < 0.05 analyzed by unpaired student’s T-test. 
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3.6 Blockage of RyR2 reduced apoptosis induced by 
H/R 
To determine whether aberrant Ca2+release via RyR2 played a role in apoptosis after H/R, 
we incubated H9c2 cells with dantrolene (100 μM), an antagonist of RyR2 which inhibits 
Ca2+ release form SR via RyR2 or vehicle, and performed H/R on these cells. Apoptosis 
was assessed by measuring caspase-3 activity. Consistently, H/R induced apoptosis in 
H9c2 cells, which was significantly reduced by dantrolene [Figure 10]. This result 
suggests that RyR2-mediated aberrant SR Ca2+ release contributes to H/R-induced 
apoptosis. 
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Figure 10: Effect of dantrolene on apoptosis in H9c2 cells following H/R 
H9c2 cells was pretreated with dantrolene (100 μM) for 30 minutes prior subjecting to 
H/R. Apoptosis was assessed by measuring caspase-3 activity. Data are mean ± SD from 
3 different experiments. *P < 0.05 and #P < 0.05 analyzed by two-way ANOVA followed 
by the Newman-Keuls test. 
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3.7 Up-regulation of JPH2 prevented calpain 
activation in H/R-stimulated cardiomyocytes. 
Dysregulation of Ca2+ induces calpain activation, which has been implicated in ischemic 
heart diseases [57, 181]. Since H/R induced aberrant Ca2+ leak from SR, we measured 
calpain activity in H/R-stimulated cardiomyocytes. H/R led to an increase in cleaved 
fragment of α-spectrin (140kDa) after reoxygenation in a time-dependent manner [Figure 
11], indicative of calpain activation as active calpain cleaves α-spectrin and releases a 
140KDa fragment. 
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Figure 11: Measurement of calpain activation in H9c2 cells following H/R 
H9c2 cells were subjected to hypoxia for 24h, and were collected separately in different 
time point after reoxygenation. A western blot for the cleavage of α-spectrin (140 kDa) 
from one experiment (not replicated) indicates calpain activation. 
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To further confirm the activation of calpain in H/R-stimulated cardiomyocytes, we 
measured its enzymatic activity. Consistently, calpain enzymatic activity was increased 
after H/R. Notably, upregulation of JPH2 by infection with Ad-JPH2 prevented calpain 
activation in H9c2 cells after H/R [Figure 12]. 
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Figure 12: Effects of JPH2 up-regulation on calpain activation in H9c2 cells 
following H/R 
H9c2 cells were infected with Ad-JPH2 or Ad-gal and then were subjected to a 24-hour 
hypoxia followed by a 24-hour reoxygenation. Calpain enzymatic activity was then 
measured in H9c2 cells. Data are mean ± SD from 3 different experiments. *P < 0.05 and 
#P < 0.05 analyzed by two-way ANOVA followed by the Newman-Keuls test. 
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3.8 Up-regulation of JPH2 attenuated ER stress in 
H/R-stimulated cardiomyocytes. 
It has been well demonstrated that ER-stress promotes apoptosis and H/R induces ER 
stress in cardiomyocyets [132, 143, 178]. Having shown that JPH2 prevented apoptosis 
induced by H/R in cardiomyocytes, we hypothesized that JPH2 inhibited H/R-induced 
ER stress. To examine this hypothesis, we infected neonatal cardiomyocytes with Ad-
JPH2 or Ad-gal and then performed H/R in these cells. H/R significantly increased the 
protein levels of GRP78, CHOP, and phosphorylated JNK1/2, indicative of ER stress. 
Upregulation of JPH2 by infection with Ad-JPH2 reduced their levels (CHOP and 
phosphorylated JNK1/2) in H/R-stimulated cardiomyocytes [Figure 13]. These results 
support our hypothesis that JPH2 inhibits ER stress induced by H/R. 
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Figure 13: Effect of JPH2 over-expression on ER stress in primary neonatal 
cardiomyocytes following H/R 
Neonatal cardiomyocytes were infected with Ad-JPH2 or Ad-gal, and then subjected to a 
24-hour hypoxia followed by a 24-hour reoxygenation. Representative western blots for 
ER stress markers from two different experiments.  
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Chapter 4  
4 Discussion, Limitation & Future direction 
4.1 Discussion 
The major finding of this study is that JPH2 prevents H/R-induced apoptosis in 
cardiomyocytes. The anti-apoptotic role of JPH2 is associated with decreased Ca2+ 
leakage through RyR2 and inhibition of calpain activation, leading to prevention of ER 
stress in H/R-stimulated cardiomyocytes. To the best of our knowledge, this is the first 
report to demonstrate that JPH2 protects cardiomyocytes against H/R-induced apoptosis. 
4.1.1 JPH2 downregulation and its contribution to apoptosis in H/R 
injury 
Down-regulation of JPH2 protein has been reported in various human heart diseases 
including hypotrophy, dilated cardiomyopathy and heart failure [77, 88, 95, 96], as well 
as in rodent models of heart diseases [93, 114, 115]. Several mechanisms have been 
demonstrated to contribute to the dysregulation of JPH2 in hearts under stress. First, early 
studies showed that upregulation of miR-24 was correlated with down-regulation of JPH2 
protein in human diseased hearts and mouse heart tissues of pressure overload-induced 
cardiac hypertrophy [183]. Importantly, inhibition of miR-24 restored the protein levels 
of JPH2 in pressure over-load-induced mouse hearts, suggesting that miR-24 may target 
and repress JPH2 protein expression [183]. Indeed, there is a putative binding site in 3’-
untranslational region of JPH2 mRNA for miR-24 and mutation of this putative binding 
site abrogated the inhibitory role of miR-24 in JPH2 expression [183]. Second, activation 
of calpain was reported to contribute to a reduction in JPH2 protein in cardiomyocytes 
following I/R and in ischemic hearts [184]. Incubation with calpain inhibitors increased 
the protein levels of JPH2 in cardiomyocytes following I/R. Further study identified 
R565T as the primary cleavage site of calpain-1 on the C-terminal of JPH2 [185]. Third, 
the functional defect of JPH2 has also been suggested. Several mutation regions in the 
gene encoding JPH2 have been affirmatively associated with the myocardial diseases 
heretofore, including S101R, Y141H, and S165F in hypertrophic cardiomyopathy (HCM) 
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[95], E169K in atrial arrhythmias [88], together with newly founded G505S and R436C  
[96], and  [186].  
The present study showed that H/R decreased the protein levels of JPH2 in 
cardiomyocytes. This result is consistent with previous reports. However, it remains 
unknown what causes the down-regulation of JPH2 in H/R-stimulated cardiomyocytes. 
Our data showed that H/R induced calpain activation in cardiomyocytes. Thus, it is 
possible that calpain activation may cleave JPH2 protein, leading to a reduction in JPH2 
protein following H/R. Whether miR-24 plays a role in JPH2 expression in our system 
requires future investigations. 
Although decreased JPH2 protein plays an important role in t-tubule remodeling in 
diseased hearts [114, 115, 117], an important finding of the present study is that JPH2 
protects cardiomyocytes against H/R-induced apoptotic cell death. Several lines of 
evidence support this conclusion. First, decreased JPH2 protein was correlated with 
apoptosis in H/R-stimulated cardiomyocytes. Second, restoration of JPH2 protein 
inhibited caspase-3 activation and DNA fragmentation induced by H/R. Third, up-
regulation of JPH2 prevented H/R-induced ER stress in cardiomyocytes. These data 
strongly support that decreased JPH2 contributes to H/R-induced cell death in 
cardiomyocytes. Given that apoptosis is implicated in myocardial injury and the 
development of heart failure following I/R, up-regulation of JPH2 may be a new 
approach to reduce I/R injury in hearts. 
4.1.2 Decreased JPH2 increases aberrant SR Ca2+ release via RyR2, 
which contributes to H/R injury 
In addition to the important role of JPH2 in T-tubule system, recent studies have 
suggested that JPH2 might also have a regulatory role in RyR2 channel stability [85, 88, 
89, 180]. However, whether JPH2 modulates RyR2-mediated aberrant SR Ca2+ leakage 
during I/R remains unclear. In the present study, we show that H/R induces aberrant SR 
Ca2+ release via RyR2 in cardiomyocytes, which agrees with previous report [187]. We 
further demonstrate that up-regulation of JPH2 reduces H/R-induced aberrant SR Ca2+ 
release via RyR2 in cardiomyocytes. This result argues that JPH2 may stabilize RyR2 
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and reduce Ca2+ leak through RyR2.  Increased cytosol Ca2+ has been implicated in 
apoptosis in cardiomyocytes through multiple mechanisms including Ca2+/calmodulin 
[188, 189], calcineurin [190, 191] and calpain [57, 181]. Thus, it is highly possible that 
JPH2 prevents H/R-induced apoptosis in cardiomyocytes by stabilizing RyR2 and 
inhibiting Ca2+ leak through RyR2. In support of this view, we further showed that 
inhibition of RyR2 remarkably attenuated apoptosis and up-regulation of JPH2 prevented 
calpain activation in H/R-stimulated cardiomyocytes. 
4.1.3 Up-regulation of JPH2 prevents Calpain activation in H/R-
stimulated cardiomyocytes 
Calpain activation has been implicated in myocardial I/R injury [181, 192, 193]. 
Specifically, pharmacological and genetic inhibition of calpain reduces myocardial I/R 
injury in a global I/R model of isolated whole hearts and in vivo myocardial I/R animal 
models [156, 160, 166, 168, 170, 194]. Our recent study further demonstrated that calpain 
activation induces ER stress, which contributes to apoptosis in H/R-stimulated 
cardiomyocytes [178]. These studies provide strong evidence in support of the role of 
calpain in myocardial I/R injury. It is well known that elevation of intracellular Ca2+ 
induces calpain activation [144]. In the present study, we report that H/R increased Ca2+ 
release from SR via RyR2 and calpain activation in cardiomyocytes.  Thus, it is possible 
that increased Ca2+ release from SR via RyR2 may result in elevation of intracellular Ca2+ 
concentration, which leads to calpain activation. In fact, our previous studies have 
demonstrated that blocking RyR2 channel prevents calpain activation in cardiomyocytes 
under septic and diabetic conditions as well as in response to norepinephrine [195-197]. 
Since up-regulation of JPH2 prevented Ca2+ release from SR via RyR2 in H/R-stimulated 
cardiomyocytes, we show that up-regulation of JPH2 decreased calpain activity. Thus, it 
is likely that JPH2 prevents H/R-induced calpain activation by inhibiting Ca2+ release 
from SR via RyR2 in cardiomyocytes.    
Interestingly, our recent study revealed that calpain targeted and cleaved JPH2 in 
ischemic hearts [179]. This raises an intriguing possibility that active calpain can 
commence a positive feedback loop that potentiates Ca2+ dysregulation through JPH2 
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cleavage, increased intracellular Ca2+ and calpain activation, leading to lethal cell injury 
following I/R.  
4.1.4 Up-regulation of JPH2 attenuates the induction of ER stress 
The sarcoplasmic reticulum(SR) collaborates with membrane T-tubules and is 
responsible for sarcomere contraction through Ca2+-induced Ca2+ release (CICR) [37, 48]. 
In contrast, perinuclear endoplasmic reticulum (ER) in cardiomyocytes supports basic 
cellular functions such as protein synthesis, folding, post-translational modification and 
stress responses [198]. Many studies have implicated ER stress-initiated apoptosis in 
ischemic heart injury [56, 133, 135, 138-142]. In our previous study, we reported that ER 
stress induced apoptosis through JNK activation in H/R-stimulated cardiomyocytes [178]. 
In the present study, we found that up-regulation of JPH2 significantly reduced ER stress 
responses and prevented JNK1/2 activation in H/R-stimulated cardiomyocytes. 
Moreover, inhibition of RyR2 prevented ER stress and reduced apoptosis in H/R-
stimulated cardiomyocytes. Thus, we argue that JPH2 inhibits H/R-induced ER stress by 
preventing RyR2-mediated Ca2+ leakage in cardiomyocytes. 
However, it is currently unknown how aberrant Ca2+ leakage via RyR2 contributes to ER 
stress in response to H/R. Our recent study demonstrated that calpain activation induced 
ER stress in cardiomyocytes and inhibition of calpain activation prevented H/R-induced 
ER stress [178]. Calpain has been shown to target and cleave Ca2+ regulatory proteins in 
SR. For example, calpain activation cleaves SERCA and RyR2 subunits, leading to 
depletion of Ca2+ in SR, which contributes to ER stress [122, 164-166]. Calpain may also 
activate caspase-12 [199, 200]. Interestingly, we show that up-regulation of JPH2 
inhibited calpain activation in H/R-stimulated cardiomyocytes. Thus, inhibition of 
calpain activation may be a possible mechanism by which JPH2 prevents ER stress in 
H/R-induced cardiomyocytes.   
In this study, we demonstrate a novel mechanism associating JPH2 to H/R-induced cell 
death. JPH2-RyR2 impairment acts as the main source of persistent Ca2+ dysregulation in 
the cardiomyocytes, which subsequently initiates a series of cellular alteration and 
ultimately leads to apoptosis. Since Ca2+ dysregulation is not exclusive to I/R injury, this 
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pattern is highly possibly involved in other kinds of cardiomyopathies, which require 
further investigation. Furthermore, the junctophilin family exists in all types of excitable 
cells and have been associated with different cell types of diseases. For instance, 
junctophilin-1 is mainly expressed in skeletal muscles and has been involved in eccentric 
contraction and prolonged muscle contraction when it loses its function [201, 
202]. Though JPH3 and JPH4 distribute slightly differently in neural sites of the brain 
[203], studies have shown that their disruptions contribute to Huntington's disease-like 2 
[204]. Based on the similarity of JMCs organized by junctophilin subtypes, the other 
members of junctophilins may also serve as regulators of their matched Ryanodine 
receptors. Therefore, other junctophilin family members (JPH1, JPH3 and JPH4) may 
provide similar protective roles other types of excitable cells. 
4.1.5 Concluding remarks 
This thesis demonstrates that H/R induces JPH2 down-regulation and increases Ca2+ 
leakage from SR through RyR2, which consequently promotes calpain activation, leading 
to ER stress and apoptosis in cardiomyocytes. Thus, upregulation of JPH2 stabilizes 
RyR2 and reduces calpain activation by preventing the persistent aberrant Ca2+ release 
from SR, therefore protecting cardiomyocytes from ER stress and lethal cell injury in 
response to H/R. This study reveals a novel role of JPH2 in inhibiting apoptosis induced 
by H/R in cardiomyocytes and suggests that up-regulating JPH2 may be a potential 
therapeutic approach to reduce I/R-induced heart injury. 
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Figure 14: Summary of the findings 
 
4.2 Limitations and future direction 
Although H9c2 cells are originally derived from embryonic BDIX rat heart tissue sharing 
plenty biological similarities to cardiomyocytes and have been widely used for cardiac 
stress studies, this cell line lacks some morphological and electronic characteristics 
compared to the freshly isolated rat cardiomyocytes [205]. One of the differences is that 
H9c2 cells are absent of spontaneous or inducible beating. So, when it came to the Ca2+ 
leakage experiment, we could not test whether the aberrant Ca2+ release alters the Ca2+ 
transients during the contraction process. Thus, for further investigations, we will conduct 
H/R and measure Ca2+ transients on isolated rodent adult cardiomyocytes with observable 
spontaneous contraction. 
Another limitation in Ca2+ leakage experiment is about the administration of caffeine. 
Caffeine is known to mobilize store Ca2+ drastically efflux from SR, which chalks up to 
its ability to reduce the release threshold of the RyR2 channel [206]. Caffeine has been 
H/R
Apoptosis
Up-regulation of JPH2Aberrant SR Ca2+ release
Downregulation of JPH2
ER-stress
Calpain activation
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used to measure SR content [207]. Unfortunately, we have not yet been able to stimulate 
Ca2+ efflux in the H9c2 with caffeine. 
Na+/Ca2+ estranger(NCX) is a major cytosolic Ca2+ extrusion channel in cardiomyocytes, 
and its dysfunction has been demonstrated to contribute to Ca2+ overload in I/R injury 
[60]. Recent studies suggest that JPH2 may also co-localize with NCX and regulates its 
activity [89]. In our future study, we will investigate whether NCX dysfunction is 
involved in the JPH2-mediated Ca2+ dysregulation of I/R injury. 
As mentioned before, caspase-12 correlates with calpain-mediated ER stress and JNK 
activation, but it has not been studied in I/R-stimulated cardiomyocytes. Thus, to clarify 
how calpain mediates ER stress, especially the pro-apoptotic JNK activation, we will 
examine caspase-12 in our future study. 
In the future, we will extend to determine the protective role of JPH2 up-regulation in 
I/R-induced heart injury in vivo by using transgenic animals. Mechanistically, we will 
investigate the molecular mechanisms by which JPH2 protects RyR2 function in 
cardiomyocytes following I/R.   
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